Clinical Trials in Boston

Showing 3421-3440 of 17,836 trials

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.

Non Small Cell Lung CancerSolid Tumors, AdultLung Cancer+1 more

Tango Therapeutics, Inc.126 participantsStarted Jun 2023

Santa Monica, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +10 more locations

COMPLETEDPhase 2< 1 mile

Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions

NCT01847209

This is a phase II protocol to determine the safety and feasibility of Intraoperative CT fluoroscopy guidance for lung resection for small nodules.

Lung Cancer

Brigham and Women's Hospital25 participantsStarted Apr 2013

Boston, Massachusetts, United States

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions

Find Trials by Condition in Boston

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

FOLFIRINOX + NIS793 in Pancreatic Cancer

MARGetuximab Or Trastuzumab (MARGOT)

Improving Health for Older Adults With Pain Through Engagement

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Building Connections

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring